Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KMDA NASDAQ:PRTC NASDAQ:PYXS NASDAQ:STRO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKMDAKamada$7.26+0.3%$8.07$6.50▼$9.35$417.52M0.8365,686 shs11,286 shsPRTCPureTech Health$17.42$17.16$14.50▼$19.92$424.04M1.1518,480 shsN/APYXSPyxis Oncology$1.71+0.5%$1.83$0.97▼$5.55$108.01M1.42618,219 shs51,219 shsSTROSutro Biopharma$26.25+1.8%$30.85$6.74▼$43.85$436.45M1.54210,873 shs84,668 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKMDAKamada0.00%-3.60%-15.32%-15.32%+3.87%PRTCPureTech Health0.00%0.00%+1.63%-0.29%-4.86%PYXSPyxis Oncology+0.59%-0.58%-37.96%+8.97%+25.93%STROSutro Biopharma+1.50%+5.57%-35.91%+5.09%+211.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKMDAKamada$7.26+0.3%$8.07$6.50▼$9.35$417.52M0.8365,686 shs11,286 shsPRTCPureTech Health$17.42$17.16$14.50▼$19.92$424.04M1.1518,480 shsN/APYXSPyxis Oncology$1.71+0.5%$1.83$0.97▼$5.55$108.01M1.42618,219 shs51,219 shsSTROSutro Biopharma$26.25+1.8%$30.85$6.74▼$43.85$436.45M1.54210,873 shs84,668 shs10 Stocks Set to Soar in 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKMDAKamada0.00%-3.60%-15.32%-15.32%+3.87%PRTCPureTech Health0.00%0.00%+1.63%-0.29%-4.86%PYXSPyxis Oncology+0.59%-0.58%-37.96%+8.97%+25.93%STROSutro Biopharma+1.50%+5.57%-35.91%+5.09%+211.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKMDAKamada 3.00Buy$12.0065.29% UpsidePRTCPureTech Health 1.00SellN/AN/APYXSPyxis Oncology 2.63Moderate Buy$6.83299.84% UpsideSTROSutro Biopharma 3.00Buy$49.1187.08% UpsideCurrent Analyst Ratings BreakdownLatest PYXS, PRTC, STRO, and KMDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/5/2026PYXSPyxis Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/28/2026STROSutro Biopharma BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$56.005/28/2026STROSutro Biopharma BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$56.005/21/2026PYXSPyxis Oncology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/18/2026PRTCPureTech Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/15/2026KMDAKamada Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)5/15/2026STROSutro Biopharma Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOutperform$38.00 ➝ $43.005/15/2026STROSutro Biopharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$28.00 ➝ $50.005/8/2026STROSutro Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/5/2026PYXSPyxis Oncology WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$6.005/4/2026STROSutro Biopharma Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 6/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKMDAKamada$180.46M2.31$0.61 per share11.86$4.68 per share1.55PRTCPureTech Health$4.66M91.01N/AN/A$12.65 per share1.38PYXSPyxis Oncology$13.86M7.81N/AN/A$0.86 per share1.99STROSutro Biopharma$102.48M4.24N/AN/A($15.43) per share-1.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKMDAKamada$20.20M$0.3520.7411.900.6611.21%7.73%5.41%8/12/2026 (Estimated)PRTCPureTech Health-$109.74MN/AN/AN/AN/AN/AN/AN/A8/27/2026 (Estimated)PYXSPyxis Oncology-$79.62M-$1.31N/AN/AN/AN/A-135.60%-85.00%8/13/2026 (Estimated)STROSutro Biopharma-$191.09M-$11.04N/AN/AN/A-154.21%N/A-69.20%8/6/2026 (Estimated)Latest PYXS, PRTC, STRO, and KMDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026KMDAKamada$0.12$0.07-$0.05$0.07$46.72 million$45.24 million5/14/2026Q1 2026PYXSPyxis Oncology-$0.35-$0.37-$0.02-$0.37$0.02 millionN/A5/14/2026Q1 2026STROSutro Biopharma-$2.7363-$2.94-$0.2037-$2.94$8.89 million$14.52 million4/10/2026H2 2025PRTCPureTech HealthN/A-$1.35N/A-$1.35N/A$1.40 million3/23/2026Q4 2025PYXSPyxis Oncology-$0.35-$0.29+$0.06-$0.29$0.13 million$11.04 million3/11/2026Q4 2025KMDAKamada$0.09$0.06-$0.03$0.06$145.07 million$44.68 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthKMDAKamada$0.192.62%N/A54.29%N/APRTCPureTech HealthN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/ASTROSutro BiopharmaN/AN/AN/AN/AN/ALatest PYXS, PRTC, STRO, and KMDA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/11/2026KMDAKamadaannual$0.253.05%3/23/20263/23/20264/7/2026(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKMDAKamadaN/A3.331.90PRTCPureTech HealthN/A6.596.59PYXSPyxis OncologyN/A2.762.76STROSutro BiopharmaN/A3.123.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKMDAKamada20.38%PRTCPureTech Health0.04%PYXSPyxis Oncology39.07%STROSutro Biopharma96.99%Insider OwnershipCompanyInsider OwnershipKMDAKamada36.10%PRTCPureTech Health5.30%PYXSPyxis Oncology10.60%STROSutro Biopharma5.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKMDAKamada36057.51 million36.75 millionOptionablePRTCPureTech Health10024.34 million23.05 millionNot OptionablePYXSPyxis Oncology6063.35 million56.64 millionOptionableSTROSutro Biopharma24016.57 million15.59 millionOptionablePYXS, PRTC, STRO, and KMDA HeadlinesRecent News About These CompaniesSutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Wall Street ZenJune 6, 2026 | americanbankingnews.comSutro Biopharma, Inc. (NASDAQ:STRO) Given Average Rating of "Buy" by BrokeragesJune 1, 2026 | americanbankingnews.comNews Flash: Analysts Just Made A Massive Upgrade To Their Sutro Biopharma, Inc. (NASDAQ:STRO) ForecastsMay 28, 2026 | finance.yahoo.comUS$47.10 - That's What Analysts Think Sutro Biopharma, Inc. (NASDAQ:STRO) Is Worth After These ResultsMay 17, 2026 | finance.yahoo.comWedbush upgrades Sutro Biopharma (STRO)May 16, 2026 | msn.comSutro Biopharma Reports First Quarter 2026 Financial Results and Business HighlightsMay 14, 2026 | globenewswire.comCitizens Lifts PT on Sutro Biopharma (STRO) on Its Pipeline and Lead ProgramMay 1, 2026 | insidermonkey.comMizuho initiates coverage of Sutro Biopharma (STRO) with outperform recommendationMay 1, 2026 | msn.comSutro Biopharma: Recycling Past Data Ahead Of The Readout, SellMay 1, 2026 | seekingalpha.comHere is Why Sutro Biopharma (STRO) is One of the Tiny Stocks That Are On Fire Right NowApril 29, 2026 | finance.yahoo.comSutro Biopharma, Inc. (STRO) Presents at AACR Annual Meeting 2026 - SlideshowApril 24, 2026 | seekingalpha.comSutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026April 19, 2026 | markets.businessinsider.comSutro Biopharma Reports Promising Preclinical Data for Next-Generation ADCs STRO-004, STRO-006, and STRO-227 at AACR Annual Meeting 2026April 19, 2026 | quiverquant.comQSutro Biopharma (NASDAQ:STRO) Trading 10.4% Higher on Analyst UpgradeApril 18, 2026 | defenseworld.netDSutro Biopharma (STRO) price target decreased by 21.62% to 29.58April 9, 2026 | msn.comSutro Biopharma (STRO) Moves 7.4% Higher: Will This Strength Last?April 8, 2026 | zacks.comLeerink Partners initiates coverage of Sutro Biopharma (STRO) with outperform recommendationApril 8, 2026 | msn.comSutro Biopharma (STRO) price target increased by 13.85% to 37.74March 27, 2026 | msn.comWells Fargo upgrades Sutro Biopharma (STRO)March 25, 2026 | msn.comHC Wainwright & Co. upgrades Sutro Biopharma (STRO)March 25, 2026 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Infrastructure Stocks Fueling the Data Center Building BoomBy Dan Schmidt | May 18, 20262 Software Stocks Turning AI Fears Into Fundamental GainsBy Dan Schmidt | May 21, 2026Will the SpaceX IPO Put These 5 Public Space Stocks Into a Higher Orbit?By Ryan Hasson | June 2, 20263 Up-and-Coming Stocks That Could Be the Next NVIDIABy Chris Markoch | June 1, 20263 Stocks With Fresh Catalysts to Watch Before the July 4By Chris Markoch | June 8, 2026PYXS, PRTC, STRO, and KMDA Company DescriptionsKamada NASDAQ:KMDA$7.26 +0.02 (+0.28%) As of 01:03 PM Eastern This is a fair market value price provided by Massive. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.PureTech Health NASDAQ:PRTC$17.42 0.00 (0.00%) As of 06/9/2026PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Pyxis Oncology NASDAQ:PYXS$1.71 +0.01 (+0.53%) As of 01:04 PM Eastern This is a fair market value price provided by Massive. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.Sutro Biopharma NASDAQ:STRO$26.25 +0.46 (+1.79%) As of 01:05 PM Eastern This is a fair market value price provided by Massive. Learn more.Sutro Biopharma, Inc. operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer. The company's pre-clinical product candidates include STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors and hematological cancers; and STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including cervical, lung, and breast cancer. Sutro Biopharma, Inc. has collaboration and license agreements with Merck Sharp & Dohme Corporation to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas FuelCell Energy Just Got a Wake-Up Call From Wall Street Uranium Energy Corp Melts Down—Nuclear Opportunity at Hand Corning Is Paving AI's Future With Glass Short Sellers Are Piling Into Wingstop, But Analysts See Big Upside Optical Cable Corporation: Strong Earnings, But Hurdles Remain The J.M. Smucker Company’s Dividend: Too Sweet to Ignore? Why's Amazon Suddenly Lagging the S&P 500, and Is It a Warning? Apple's Siri AI Was Finally Announced, So Why Is the Stock Tanking? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
